Please use this identifier to cite or link to this item:
Title: Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer
Author: Blasco-Benito, Sandra
Moreno Guillén, Estefanía
Seijo-Vila, Marta
Tundidor, Isabel
Andradas, Clara
Caffarel, María M.
Caro-Villalobos, Miriam
Urigüen, Leyre
Diez-Alarcia, Rebeca
Moreno-Bueno, Gema
Hernández, Lucía
Manso, Luis
Homar Ruano, Patricia C.
McCormick, Peter J.
Bibic, Lucka
Bernadó Morales, Cristina
Arribas, Joaquín V. (Vicente)
Canals Buj, Meritxell
Casadó, Vicent
Canela Campos, Enric I.
Guzmán, Manuel
Pérez-Gómez, Eduardo
Sánchez Mora, Cristina
Keywords: Càncer de mama
Breast cancer
Issue Date: 26-Feb-2019
Publisher: National Academy of Sciences
Abstract: There is a subtype of breast cancer characterized by the overexpression of the oncogene HER2. Although most patients with this diagnosis benefit from HER2-targeted treatments, some do not respond to these therapies and others develop resistance with time. New tools are therefore warranted for the treatment of this patient population, and for early identification of those individuals at a higher risk of developing innate or acquired resistance to current treatments. Here, we show that HER2 forms heteromer complexes with the cannabinoid receptor CB2R, the expression of these structures correlates with poor patient prognosis, and their disruption promotes antitumor responses. Collectively, our results support HER2-CB2R heteromers as new therapeutic targets and prognostic tools in HER2+ breast cancer
Note: Reproducció del document publicat a:
It is part of: Proceedings of the National Academy of Sciences of the United States of America - PNAS, 2019, vol. 116, num. 9, p. 3863-3872
Related resource:
ISSN: 0027-8424
Appears in Collections:Articles publicats en revistes (Bioquímica i Biomedicina Molecular)

Files in This Item:
File Description SizeFormat 
685639.pdf2.52 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.